Sociedad Americana de Hirudoterapia

In situ hybridization reveals transient laminin B-chain expression by individual glial and muscle cells in embryonic leech central nervous system.

Research article published in Journal of neurobiology (1995)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Genómica y proteómicaFarmacología salivalLuebke et al. · Journal of neurobiology, 1995

Abstract

Laminin, which strongly stimulates axon outgrowth in vitro, appears transiently within the central nervous system (CNS) in embryos. After CNS injury, laminin reportedly reappears along axonal pathways only in animal species in which central axon regeneration is successful, including the leech Hirudo medicinalis. Although glia have been suspected of making CNS laminin, in adult leeches glia are not required for laminin synthesis and evidently microglia, not present in the early embryo, produce laminin. To determine which embryonic cells make laminin, a 1.2 kb DNA fragment of leech laminin B1 chain, with homology to Drosophila, human, and mouse B1 laminins and rat S laminin, was isolated using reverse-transcription and degenerate polymerase chain reaction (PCR) cloning. In situ hybridization revealed that laminin expression began before embryonic day 8, and by days 8 and 9 it was seen in paired CNS muscle cells. By late day 9, the two neuropil glial cells began to express laminin. Lucifer Yellow dye was injected intracellularly and muscle cells stimulated to contract, confirming the identities of muscle and glial cells. Packet glial cells began to express B1 laminin by embryonic day 12. By day 15, the cells of the perineurial sheath expressed B1 laminin, whereas it was no longer detectable in CNS muscle and glia. The results agree with published immunohistochemistry showing laminin within the CNS among growing axons by day 8, and only later in the perineurial sheath, by which time laminin disappears from within the CNS. Therefore, different cells synthesize laminin in the embryo and during repair in adults.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov'tResearch Support, U.S. Gov't, Non-P.H.S.Research Support, U.S. Gov't, P.H.S.
Indexed MeSH termsAmino Acid SequenceAnimalsBase SequenceCentral Nervous SystemEmbryo, NonmammalianGene Expression Regulation, DevelopmentalIn Situ HybridizationLamininLeechesMolecular Sequence DataNerve Tissue ProteinsNeuroglia

Resumen

Laminin, which strongly stimulates axon outgrowth in vitro, appears transiently within the central nervous system (CNS) in embryos. After CNS injury, laminin reportedly reappears along axonal pathways only in animal species in which central axon regeneration is successful, including the leech Hirudo medicinalis.

Por qué esto importa para la hirudoterapia

This study used in situ hybridization to characterize the temporal and cellular pattern of laminin B1-chain gene expression in the embryonic central nervous system of the leech Hirudo medicinalis, identifying a 1.2 kb DNA fragment with homology to Drosophila, human, and mouse B1 laminins. The authors found that paired CNS muscle cells expressed laminin by embryonic days 8–9, followed by neuropil glial cells, and that different cell types synthesize laminin during embryogenesis versus during adult CNS repair. This study is relevant to ASH's domain insofar as it advances fundamental understanding of the developmental and regenerative biology of Hirudo medicinalis, the primary species used in hirudotherapy. Caveat: This is a basic developmental neuroscience study examining extracellular matrix gene expression in leech embryos; it has no direct bearing on hirudotherapy practice, the leech secretome, or clinical applications of leech therapy.

Citación

In situ hybridization reveals transient laminin B-chain expression by individual glial and muscle cells in embryonic leech central nervous system.

Luebke et al. · Journal of neurobiology, 1995

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.